SRS Capital Advisors Inc. lifted its holdings in Pfizer Inc. (NYSE:PFE) by 10.8% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 18,136 shares of the biopharmaceutical company’s stock after acquiring an additional 1,766 shares during the period. SRS Capital Advisors Inc.’s holdings in Pfizer were worth $657,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. FCG Advisors LLC raised its stake in shares of Pfizer by 43.9% in the 1st quarter. FCG Advisors LLC now owns 13,125 shares of the biopharmaceutical company’s stock valued at $466,000 after buying an additional 4,007 shares in the last quarter. Claraphi Advisory Network LLC raised its stake in shares of Pfizer by 26.0% in the 1st quarter. Claraphi Advisory Network LLC now owns 22,695 shares of the biopharmaceutical company’s stock valued at $805,000 after buying an additional 4,676 shares in the last quarter. Asset Management One Co. Ltd. raised its stake in shares of Pfizer by 2.2% in the 1st quarter. Asset Management One Co. Ltd. now owns 9,836,917 shares of the biopharmaceutical company’s stock valued at $349,113,000 after buying an additional 214,474 shares in the last quarter. Principal Financial Group Inc. raised its stake in shares of Pfizer by 1.0% in the 1st quarter. Principal Financial Group Inc. now owns 15,135,014 shares of the biopharmaceutical company’s stock valued at $537,141,000 after buying an additional 149,146 shares in the last quarter. Finally, CT Mason raised its stake in shares of Pfizer by 26.8% in the 1st quarter. CT Mason now owns 107,654 shares of the biopharmaceutical company’s stock valued at $3,821,000 after buying an additional 22,734 shares in the last quarter. 69.42% of the stock is owned by hedge funds and other institutional investors.
In related news, major shareholder Pfizer Inc acquired 55,556 shares of the firm’s stock in a transaction on Monday, October 15th. The shares were purchased at an average price of $18.00 per share, with a total value of $1,000,008.00. Following the acquisition, the insider now directly owns 21,976,484 shares in the company, valued at $395,576,712. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. 0.06% of the stock is owned by corporate insiders.
Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, October 30th. The biopharmaceutical company reported $0.78 EPS for the quarter, topping analysts’ consensus estimates of $0.75 by $0.03. Pfizer had a net margin of 44.63% and a return on equity of 25.26%. The firm had revenue of $13.30 billion for the quarter, compared to analyst estimates of $13.53 billion. During the same quarter in the prior year, the firm earned $0.67 EPS. The company’s revenue was up 1.0% on a year-over-year basis. Analysts expect that Pfizer Inc. will post 3 earnings per share for the current fiscal year.
The business also recently disclosed a quarterly dividend, which was paid on Monday, December 3rd. Shareholders of record on Friday, November 9th were issued a dividend of $0.34 per share. This represents a $1.36 dividend on an annualized basis and a yield of 3.10%. The ex-dividend date was Thursday, November 8th. Pfizer’s dividend payout ratio is currently 51.32%.
A number of brokerages have recently issued reports on PFE. Credit Suisse Group set a $42.00 price objective on shares of Pfizer and gave the company a “hold” rating in a research note on Monday, November 26th. JPMorgan Chase & Co. restated a “buy” rating and issued a $42.00 price objective on shares of Pfizer in a research note on Thursday, August 23rd. Atlantic Securities reaffirmed a “buy” rating and issued a $54.00 target price on shares of Pfizer in a report on Tuesday, November 27th. Societe Generale set a $43.00 target price on shares of Pfizer and gave the stock a “hold” rating in a report on Thursday, November 1st. Finally, Cantor Fitzgerald reaffirmed a “buy” rating and issued a $53.00 target price on shares of Pfizer in a report on Monday, November 19th. Two equities research analysts have rated the stock with a sell rating, fifteen have assigned a hold rating and nine have issued a buy rating to the company. The company presently has an average rating of “Hold” and an average target price of $43.27.
ILLEGAL ACTIVITY WARNING: “Pfizer Inc. (PFE) Stake Boosted by SRS Capital Advisors Inc.” was published by BBNS and is the property of of BBNS. If you are reading this news story on another publication, it was illegally copied and republished in violation of United States & international copyright law. The legal version of this news story can be viewed at https://baseballnewssource.com/2018/12/08/pfizer-inc-pfe-stake-boosted-by-srs-capital-advisors-inc/3065123.html.
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.
See Also: How dollar cost averaging works
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.